The exercise of warrants, which can occur at any time from September 24, 2013 to September 24, 2022, will lead to an increase in the Publicis Groupe’s capital stock. The conversion ratio was adjusted again during the financial year by a factor of 1,116 to reflect the distributions drawn from the Company’s reserves and premiums. Following the cancellation of the warrants acquired in previous years or exercised since September 24, 2013, Publicis Groupe was, as of December 31, 2021, committed to issuing (in the event that the 529,895 outstanding stock warrants are exercised) 591,363 shares with a euro 0.40 par value and a euro 30.10 premium.
As of December 31, 2021, there were no significant commitments such as pledges, guarantees or collateral, or any other significant off-balance sheet commitments, in accordance with currently applicable accounting standards.
|
(in millions of euros) |
Value in balance sheet | Fair value through profit and loss | Amortized cost | Fair value through OCI |
|---|---|---|---|---|
| Other financial assets | Other financial assets Value in balance sheet
|
Other financial assets Fair value through profit and loss
|
Other financial assets Amortized cost
|
Other financial assets Fair value through OCI
|
|
154 |
154 |
|
|
|
12 |
12 |
|
|
|
35 |
|
35 |
|
|
75 |
|
75 |
|
| Trade receivables | Trade receivablesValue in balance sheet 11,315 |
Trade receivablesFair value through profit and loss
|
Trade receivablesAmortized cost 11,315 |
Trade receivablesFair value through OCI
|
| Other current receivables and current assets(1) | Other current receivables and current assets (1)Value in balance sheet
|
Other current receivables and current assets (1)Fair value through profit and loss
|
Other current receivables and current assets (1)Amortized cost
|
Other current receivables and current assets (1)Fair value through OCI
|
|
8 |
8 |
|
|
|
13 |
13 |
|
|
|
155 |
|
155 |
|
| Total financial instruments – assets | Total financial instruments – assetsValue in balance sheet11,767 | Total financial instruments – assetsFair value through profit and loss187 | Total financial instruments – assetsAmortized cost11,580 | Total financial instruments – assetsFair value through OCI- |
| Long-term borrowings | Long-term borrowings Value in balance sheet3,446 |
Long-term borrowings Fair value through profit and loss
|
Long-term borrowings Amortized cost3,446 |
Long-term borrowings Fair value through OCI
|
| Trade payables | Trade payables Value in balance sheet14,479 |
Trade payables Fair value through profit and loss
|
Trade payables Amortized cost14,479 |
Trade payables Fair value through OCI
|
| Short-term borrowings | Short-term borrowings Value in balance sheet184 |
Short-term borrowings Fair value through profit and loss
|
Short-term borrowings Amortized cost184 |
Short-term borrowings Fair value through OCI
|
| Other creditors and current liabilities(2) | Other creditors and current liabilities (2)Value in balance sheet
|
Other creditors and current liabilities (2)Fair value through profit and loss
|
Other creditors and current liabilities (2)Amortized cost
|
Other creditors and current liabilities (2)Fair value through OCI
|
|
10 |
10 |
|
|
|
21 |
21 |
|
|
|
97 |
|
|
97 |
|
214 |
|
214 |
|
| Total financial instruments – liabilities | Total financial instruments – liabilitiesValue in balance sheet18,451 | Total financial instruments – liabilitiesFair value through profit and loss31 | Total financial instruments – liabilitiesAmortized cost18,323 | Total financial instruments – liabilitiesFair value through OCI97 |
